Shyld AI, a healthcare technology company building "active intelligence" for hospitals, has raised a $13.4 million seed round, one of the largest early-stage rounds in the healthcare AI sector. The round was led by Aulis Capital and will fund expansion across US health systems.
From passive to "active" AI
Founded by brothers Mohammad and Morteza Noshad, Shyld is building agentic AI systems that take real-time action inside hospitals. While most healthcare AI remains ambient and passive, Shyld's agents execute operational tasks across operating-room workflows, patient safety, compliance and infection control. In operating rooms, the agents interpret case progression, turnover phases and staff movement to optimize disinfection timing, flag missing supplies and reduce scheduling bottlenecks.
An edge-native foundation model
Powering the system is Vertex, Shyld's proprietary foundation model designed for edge-native, real-time agentic AI in physical environments. Unlike cloud-dependent tools, Vertex runs directly on Shyld devices inside hospital rooms, enabling continuous perception, reasoning and action without latency or reliance on hospital IT, while preserving privacy. The shift toward on-device AI is a recurring theme across the industry.
Tackling hospital infections
The company's flagship product pairs AI with UV-C light to autonomously disinfect hospital environments, targeting healthcare-associated infections that contribute to roughly 72,000 hospital deaths a year in the US, according to CDC data. A Stanford University study published in the American Journal of Infection Control found the system reduced contamination by more than 93% compared with a control room. The work complements other hospital-focused robotics such as autonomous medical transport and next-generation medical robots.
Scaling across health systems
"We're moving the industry from passive AI to Active AI," said CEO Mohammad Noshad, describing technology that "understands how hospitals actually operate and improves workflows in real time without adding burden to clinical teams." With the new capital, Shyld plans to accelerate deployments and expand into regulated cleanroom environments and pharmaceutical manufacturing, joining a wave of clinical AI entering everyday care.
Investors back rapid adoption
The seed round was led by Aulis Capital, a firm with offices in Palo Alto, Shanghai and Hong Kong and led by Nisa Leung and Skip Fleshman. "What stands out about Shyld AI is the pace at which it's being adopted across health systems," Fleshman said. "That kind of velocity is rare in healthcare. It comes from a fundamental shift from passive, ambient AI to active intelligence." Shyld says the new funding will help it broaden its Active AI capabilities beyond infection control into additional clinical and industrial settings where real-time, on-site decision-making matters.
Reporting based on coverage from Robotics & Automation News.